Highlight
- Short-term mortality in severe alcohol-associated hepatitis (sAH) remains high, with pooled 28-day mortality around 27%.
- Mortality rates progressively increase with longer follow-up, reaching over 40% at 90 days.
- No statistically significant improvement in short-term mortality has been observed over the last four decades despite clinical advances.
- The Model for End-Stage Liver Disease (MELD) score is a significant predictor of mortality, highlighting its role in risk stratification.
Study Background
Severe alcohol-associated hepatitis is a life-threatening inflammatory liver condition precipitated by excessive alcohol consumption, often superimposed on chronic liver disease. It carries a high short-term mortality risk and imposes a substantial clinical burden worldwide. Despite advances in supportive care and pharmacologic interventions such as corticosteroids, effective treatments remain limited, and prognosis remains poor. Understanding mortality trends over time and identifying key prognostic factors are crucial for guiding clinical decision-making, optimizing therapeutic strategies, and improving patient outcomes.
Study Design
This comprehensive systematic review and meta-analysis included 34 studies with a total of 1586 patients diagnosed with severe alcohol-associated hepatitis. The researchers searched PubMed, EMBASE, and Scopus databases from their inception until February 2024, selecting studies reporting mortality at key short-term intervals: 28, 60, and 90 days. Mortality data were pooled using random-effects meta-regression models to account for heterogeneity across studies. The I2 statistic quantified heterogeneity, and subgroup analyses alongside meta-regression explored potential sources of variability. Notably, Bayesian mixed-effects binomial models were employed to update the estimation of mortality probabilities over calendar time, aiming to elucidate mortality trends across five decades.
Key Findings
The meta-analysis demonstrated that pooled mortality in severe alcohol-associated hepatitis was 26.8% at 28 days (95% CI 21.0%-33.5%), rose to 35.1% at 60 days (95% CI 28.3%-42.5%), and further increased to 43.7% at 90 days (95% CI 34.6%-53.3%). This trend indicates a substantial and progressive risk of death over the critical early months following diagnosis.
Despite improvements in clinical care over the decades, the formal decade-based analysis did not detect statistically credible improvements in short-term mortality across the last 40 years. Bayesian analysis, however, showed a decline in average 28-day mortality from over 50% in studies from the 1970s to approximately 25% after 2000, suggesting some early gains that have plateaued.
Considerable heterogeneity was present (I2 > 80%), likely reflecting variations in patient populations, diagnostic criteria, and management approaches. Multivariable analysis identified the MELD score as a significant independent predictor of mortality, emphasizing its utility in clinical risk assessment in sAH.
Expert Commentary
The persistently high mortality rates in severe alcohol-associated hepatitis underscore an unmet clinical need that remains despite decades of research and evolving care practices. Current therapeutic options, including corticosteroids, have limited effectiveness and may not substantially alter long-term survival. The lack of statistically significant decline in mortality in recent decades indicates that breakthroughs in therapeutics or management strategies have been sparse or insufficient.
The significant association between MELD score and mortality aligns with mechanistic insights: MELD incorporates indicators of liver dysfunction (bilirubin, INR, creatinine), which are prognostically relevant in this condition. This supports continued use of MELD for prognostication and patient selection, including for consideration of early liver transplantation.
However, the substantial heterogeneity among studies calls for standardized diagnostic criteria, uniform treatment protocols, and comprehensive data collection in future research. Given the poor outcomes and limited therapeutic responsiveness, the findings bolster the argument for prioritizing clinical trials of novel interventions, optimizing patient selection for transplantation, and developing robust prognostic models integrating clinical, biochemical, and possibly novel biomarkers.
Conclusion
In conclusion, this meta-analysis highlights that severe alcohol-associated hepatitis remains a condition with alarmingly high short-term mortality that has not meaningfully improved over the past four decades. Despite some early gains, the plateau in mortality reduction signals a pressing need for innovative, effective treatments. Accurate prognostication, exemplified by the MELD score’s predictive value, is essential in guiding clinical decisions, including timely referral for transplantation. Moving forward, concerted efforts are needed in research to develop targeted therapies and integrate multidisciplinary care pathways to ameliorate outcomes in this challenging patient population.
References
1. Siddique MR, Haque M, Idalsoaga F, Diaz LA, Im G, Singal AK, Hoang S, Khan MQ, Arab JP. Meta-Analysis: Mortality Trends and Risk Factors in Severe Alcohol-Associated Hepatitis. Aliment Pharmacol Ther. 2025 Sep 20. doi: 10.1111/apt.70383. Epub ahead of print. PMID: 40974371.
2. Lao TT, Singal AG. Alcoholic Hepatitis: Pathogenesis and Treatment. Gastroenterology. 2022;162(3):789-799.
3. Thursz M, Richardson P, Allison M, et al. Prednisolone or Pentoxifylline for Alcoholic Hepatitis. N Engl J Med. 2015;372(17):1619-1628.
4. Mathurin P, Moreno C, Samuel D, et al. Early Liver Transplantation for Severe Alcoholic Hepatitis. N Engl J Med. 2011;365(19):1790-1800.
